Status:

UNKNOWN

Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study

Lead Sponsor:

Hospital de Clinicas de Porto Alegre

Conditions:

Heart Failure

Anemia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

Anemia has been demonstrated to be a common finding in patients with heart failure (HF). Previous studies in hospitalized patients with HF have found a prevalence of anemia ranging from 15% to 63%. Mo...

Detailed Description

The IRON-HF study is an investigator initiated, multicenter, prospectively designed,randomized, double-blind, placebo controlled clinical trial. Randomization:Each of the eight participating centers ...

Eligibility Criteria

Inclusion

  • 18 years of age or older;
  • Outpatients followed at a HF Clinic in a tertiary care Hospital with clinical diagnosis of HF for at least 3 months before study entry;
  • NYHA functional class II to IV, who are able to perform ergospirometry;
  • Documentation of LVEF \< 40% within the last 6 months;
  • Adequate baseline therapy for HF based on patient's functional class (β-blockers, ACE inhibitors irrespective of functional class except if contra-indications, digoxin, spironolactone if NYHA class III or IV);
  • Stable baseline HF therapy with same doses of medications and no intent to increase doses for the following 3 months;
  • Hemoglobin ≤ 12 g/dl and \> 9 g/dl;
  • Transferrin saturation \< 20% and ferritin \< 500 µg/L;
  • Ability to provide written informed consent.

Exclusion

  • Any clinically overt bleeding: gastrointestinal bleeding, hypermenorrhea, history of peptic ulcer without evidence of healing or inflammatory intestinal diseases;
  • Uncorrected hypothyroidism;
  • Other inflammatory, neoplastic or infectious disease;
  • Serum creatinine \> 1,5 mg/dl;
  • Previous intolerance to oral elemental iron compounds;
  • HF due to alcoholic cardiomyopathy, current regular drinker of alcoholic beverages or HF due to peripartum cardiomyopathy;
  • Recent admission for decompensated HF (last month)
  • Recent myocardial revascularization procedures (last 3 months);
  • Recent ACS, stroke or TIA (last 3 months);
  • Active or metastatic neoplastic disease with life expectancy of less than a year;
  • Patients in heart transplantation list;
  • Patients that had participated in any other clinical trial or study within the last month;
  • Pregnant or lactating women;
  • Pre-menopausal women that are not using any effective method of contraception;
  • Patients using prohibited medications or that have not yet accomplished the wash-out period;
  • Patients currently participating in cardiovascular rehabilitation programs.

Key Trial Info

Start Date :

August 1 2006

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

117 Patients enrolled

Trial Details

Trial ID

NCT00386126

Start Date

August 1 2006

Last Update

October 11 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cardiovascular Division, Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil, 90035-003